XTX Topco Ltd Acquires Shares of 4,578 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

XTX Topco Ltd bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent filing with the SEC. The fund bought 4,578 shares of the biotechnology company’s stock, valued at approximately $723,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SRPT. Innealta Capital LLC bought a new stake in Sarepta Therapeutics in the second quarter worth about $31,000. Mather Group LLC. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. New Covenant Trust Company N.A. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth approximately $32,000. Finally, Principal Securities Inc. purchased a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $26,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the transaction, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $127.21 on Monday. The stock has a market cap of $12.02 billion, a price-to-earnings ratio of 1,156.45 and a beta of 0.81. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The business has a 50-day simple moving average of $137.26 and a 200 day simple moving average of $132.75. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.27) EPS. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on SRPT shares. Barclays decreased their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. BMO Capital Markets boosted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Evercore ISI raised shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and dropped their price objective for the company from $185.00 to $179.00 in a report on Thursday, August 8th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $152.00 price target on shares of Sarepta Therapeutics in a research note on Friday. Three investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $187.39.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.